{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T17:20:50Z","timestamp":1649006450149},"reference-count":35,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2009]]},"DOI":"10.1507\/endocrj.k09e-048","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T05:59:44Z","timestamp":1256623184000},"page":"851-858","source":"Crossref","is-referenced-by-count":0,"title":["Additional Beneficial Effects of Recombinant Growth Hormone in Alendronate-treated Patients with Idiopathic Osteoporosis"],"prefix":"10.1507","volume":"56","author":[{"given":"Renata Francioni","family":"LOPES","sequence":"first","affiliation":[{"name":"Division of Endocrinology of Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Medina","family":"COELI","sequence":"additional","affiliation":[{"name":"Division of Endocrinology of Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"VAISMAN","sequence":"additional","affiliation":[{"name":"Division of Endocrinology of Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Fleiuss de","family":"FARIAS","sequence":"additional","affiliation":[{"name":"Division of Endocrinology of Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.11.3951"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Pietschmann P, Kudlacek S, Grisar J, <I>et al. <\/I>(2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. <I>Eur J Clin Invest <\/I>31: 444-451.","DOI":"10.1046\/j.1365-2362.2001.00836.x"},{"key":"3","unstructured":"3. Kurland ES, Chan FKW, Rosen CJ, Bilezikian JP (1998) Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. <I>J Clin Endocrinol Metab <\/I>83: 2576-2579."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ljunghall S, Johannsson AG, Burman P, Kampe O, Lindh E, Karlsson FA (1992) Low plasma levels of IGF-1 in male patients with idiopathic osteoporosis. <I>J Intern Med <\/I>232: 59-64.","DOI":"10.1111\/j.1365-2796.1992.tb00550.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Reed BY, Zerwekh JE, Sakhaee K, Breslau NA, Gorrschalk F, Pak CYC (1995) Serum IGF-1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. <I>J Bone Miner Res <\/I>10: 1218-1224.","DOI":"10.1002\/jbmr.5650100812"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Khosla S (1997) Editorial: Idiopathic osteoporosis-is the osteoblast to blame? <I>J Clin Endocrinol Metab <\/I>82: 2792-2794.","DOI":"10.1210\/jc.82.9.2792"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rosen CJ, Kurland ES, Vereault D, Adler RA, Rackoff PJ, Craig WY (1998) Association between serum insulin- growth-factor 1 (IGF-1) and a simple repeat in IGF-1 gene: implications for genetic studies of bone mineral density. <I>J Clin Endocrinol Metab <\/I>83: 2286-2290.","DOI":"10.1210\/jcem.83.7.4964"},{"key":"8","unstructured":"8. Rivadeneira F, Houwing-Duistermaat J, Pols HA,Van Dujin CM, Uitterlinden AG (2002) Insulin-likegrowth- factor 1 (IGF-1) gene promoter polymorphism and the risk of fracture in the elderly: The Rotterdam study. <I>J Bone Miner Res <\/I>17:S 177."},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.6.2143"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Rosen CJ, Bilezikian JP. Anabolic therapy for osteoporosis (2001) <I>J Clin Endocrinol Metab <\/I>86: 957-964.","DOI":"10.1210\/jcem.86.3.7366"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nilsson AG (2000) Effects of growth hormone replacement therapy on bone markers and bone mineral density in growth hormone-deficient adults. <I>Horm Res <\/I>54: 52-57.","DOI":"10.1159\/000063448"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Stabnov L, Kasukawa Y, Guo R, <I>et al. <\/I>(2002) Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. <I>Bone <\/I>30: 909-916.","DOI":"10.1016\/S8756-3282(02)00738-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Biermansz NR, Hamdy NAT, Janssen YJH, Roelfsema F (2001) Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy randomized controlled trial. <I>J Clin Endocrinol Metab <\/I>86: 3079-3085.","DOI":"10.1210\/jcem.86.7.7669"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Liberman UA, Weiss SR, Broll J, <I>et al. <\/I>(1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. <I>N Engl J Med <\/I>333: 1437-1443.","DOI":"10.1056\/NEJM199511303332201"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030897"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010845"},{"key":"17","unstructured":"17. Cohen A, Ebeling P, Sprague S, Shane E (2003) Transplantation osteoporosis. In: Favus MJ ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 5<SUP>th<\/SUP> ed. Washington D.C. 370-379."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. <I>N Engl<\/I><I> J Med <\/I>339: 292-299.","DOI":"10.1056\/NEJM199807303390502"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00298723"},{"key":"20","unstructured":"20. Biller BMK, Sesmilo G, Baum HBA, Hayden D, Schoenfeld D, Klibanski A (2000) Withdrawal of longterm physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult onset GH-deficiency. <I>J Clin Endocrinol Metab <\/I>85: 970-976."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Concei&ccedil;&atilde;o FL, Boguszewski CL, Meister LHF, <I>et al. <\/I>(2003) Defici&ecirc;ncia de GH em adultos: Resultados do Estudo Multic&ecirc;ntrico Brasileiro. <I>Arq Bras Endocrinol Metab <\/I>47: 312-322.","DOI":"10.1590\/S0004-27302003000400004"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.2865"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1400545"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Golden NH, Kreitzer P, Jacobson MS, <I>et al. <\/I>(1994) Disturbances in growth hormone secretion and action in adolescents with anorexia nervosa. <I>J Pediatr <\/I>125: 655-660.","DOI":"10.1016\/S0022-3476(94)70030-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K (1999) Effect of recombinanthuman growth hormone in elderly osteoporotic women. <I>Clin Endocrinol (Oxf) <\/I>51: 715-724.","DOI":"10.1046\/j.1365-2265.1999.00867.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Gillberg P, Mallmin H, Petren-Mallmin M, Lunghall S, Nilsson AG (2002) Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. <I>J Clin Endocrinol Metab <\/I>87: 4900-4906.","DOI":"10.1210\/jc.2002-020231"},{"key":"27","unstructured":"27. Johannsson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall S (1996) Effects of growth hormone and insulin-like growth factor-I in men with idiopathic osteoporosis. <I>J Clin Endocrinol Metab <\/I>81: 44-48."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kann P, Piepkorn B, Schehler B, et al (1998) Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GHdeficient adults. <I>Clin Endocrinol (Oxf) <\/I>48: 561-568.","DOI":"10.1046\/j.1365-2265.1998.00439.x"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.2.550"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Johannsson AG, Eden Engstrom B, Ljunghall S, Karlsson FA, Burman P (1999) Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. <I>J Clin Endocrinol Metab <\/I>84: 2002-2007.","DOI":"10.1210\/jc.84.6.2002"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Riggs BL, Khosla S, Melton III LJ (2002) Sex steroids and the construction and conservation of the adult skeleton. <I>Endocr Rev <\/I>23: 279-302.","DOI":"10.1210\/edrv.23.3.0465"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Christmas C, O&rsquo;Connor KG, Harman SM, <I>et al. <\/I>(2002) Growth hormone and sex steroid effects on bone metabolism and bone mineral density in healthy aged women and men. <I>J Gerontology <\/I>57: 12-18.","DOI":"10.1093\/gerona\/57.1.M12"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. van der Klaauw AA, Biermasz NR, Zelissen PMJ, <I>et al. <\/I>(2007) Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. <I>Eur J Endocrinol <\/I>157: 709-716.","DOI":"10.1530\/EJE-07-0412"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Duschek EJJ, Gooren LJ, Netelenbos C (2005) Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin- like growth factor-1 and insulin-like growth factor binding protein-3. <I>Maturitas <\/I>51: 286-293.","DOI":"10.1016\/j.maturitas.2004.08.011"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bravenboer N, Holzmann P, de Boer H, Roos JC, Van der Veen EA, Lips P (1997) The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men. <I>J Clin Endocrinol Metab <\/I>82: 1818-1822.","DOI":"10.1210\/jcem.82.6.3982"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/56\/7\/56_K09E-048\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:51:19Z","timestamp":1618296679000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/56\/7\/56_K09E-048\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.k09e-048","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}